This video illustrates a laparoscopic, robot-assisted hemidiaphragm plication.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Thoracic
August 22, 2015
Among patients with blunt trauma, the authors studied the implications of pneumomediastinum identified on CT. The incidence was 2.2%. Pneumomediastinum was associated with a 4-fold increase in mortality, a 2-fold increase in length of stay, and a 3-fold increase in ICU stay. Air in the posterior mediastinum, air in all mediastinal compartments, an
August 22, 2015
This comprehensive review outlines changes in the WHO classification of lung tumors, chagnes that will affect our clinical practice in the near future.
August 20, 2015
Thus far, only 3 randomized controlled trials (RCTs) have compared stereotactive ablative radiotherapy (SABR) versus surgery in patients with early stage NSCLC (STARS trial, ROSEL trial, and ACOSOG Z4099 trial). Unfortunately all 3 were unable to meet the accrual goals and were closed early.
August 20, 2015
This expert opinion editorial is published in JTCVS in response to the article by Chang and colleagues. Meyers and colleagues begin by emphasizing that a large randomized controlled trial (RCT) would be the best way to answer the question of whether SABR or lobectomy is superior treatment for patients with early stage NSCLC.
August 20, 2015
This is a letter in response to the article by Chang and colleagues.
August 20, 2015
This is a letter in response to the article by Chang and colleagues. The authors warn to interpret the findings of the original article, that SABR is better tolerated and might lead to improved survival compared to surgery for good risk patients with clinical stage I NSCLC, with caution. They highlight two pitfalls of the original study.
August 20, 2015
This is a letter in response to the article by Chang and colleagues. The authors begin by stating that the data from this study should be graded according to an internationally accepted system, GRADE.
August 19, 2015
This is a letter in response to the article by Chang and colleagues. The authors state that this type of analysis was necessary as it is difficult to conduct a clinical trial that involves new technology.
August 19, 2015
This is the authors' reply to the letters submitted to The Lancet Oncology. They begin by stating that the strength of their analysis was that patients were randomised, thereby avoiding selection bias. With regards to low accrual, one major factor was failure of thoracic surgeons to participate. In addition, stage I NSCLC is relatively uncommon.